[Asia Economy Reporter Minwoo Lee] On the 10th, SillaJen announced that it has applied for a dose escalation and safety/efficacy evaluation of Pexa-Vec combined with Semiplimab (REGN2810, anti-PD-1) in subjects with metastatic or unresectable renal cell carcinoma (RCC, kidney cancer), as well as a change in the Phase 1b/2a clinical trial plan.
The company explained, "Through this clinical trial, we will evaluate the safety, antitumor activity, and efficacy of Pexa-Vec combined with Semiplimab in subjects with renal cell carcinoma."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
